Epigenetics in cancer: Targeting chromatin modifications

被引:349
作者
Ellis, Leigh [1 ]
Atadja, Peter W. [2 ]
Johnstone, Ricky W. [1 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia
[2] Novartis Inst Biomed Res, Cambridge, MA USA
基金
英国医学研究理事会;
关键词
HISTONE-DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITOR; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENES; IN-VIVO ACTIVITY; DNA METHYLATION; CLASS-II; DEMETHYLATING AGENTS; CLINICAL DEVELOPMENT; THERAPEUTIC TARGETS;
D O I
10.1158/1535-7163.MCT-08-0860
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Posttranslational modifications to histones affect chromatin structure and function resulting in altered gene expression and changes in cell behavior. Aberrant gene expression and altered epigenomic patterns are major features of cancer. Epigenetic changes including histone acetylation, histone methylation, and DNA methylation are now thought to play important roles in the onset and progression of cancer in numerous tumor types. Indeed dysregulated epigenetic modifications, especially in early neoplastic development, may be just as significant as genetic mutations in driving cancer development and growth. The reversal of aberrant epigenetic changes has therefore emerged as a potential strategy for the treatment of cancer. A number of compounds targeting enzymes that regulate histone acetylation, histone methylation, and DNA methylation have been developed as epigenetic therapies, with some demonstrating efficacy in hematological malignancies and solid tumors. This review highlights the roles of epigenetic modifications to histones and DNA in tumorigenesis and emerging epigenetic therapies being developed for the treatment of cancer. [Mol Cancer Ther 2009;8(6):1409-20]
引用
收藏
页码:1409 / 1420
页数:12
相关论文
共 120 条
[101]   Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage [J].
Solomon, JM ;
Pasupuleti, R ;
Xu, L ;
McDonagh, T ;
Curtis, R ;
DiStefano, PS ;
Huber, LJ .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (01) :28-38
[102]   Increased expression of historic deacetylase 2 is found in human gastric cancer [J].
Song, J ;
Noh, JH ;
Lee, JH ;
Eun, JW ;
Ahn, YM ;
Kim, SY ;
Lee, SH ;
Park, WS ;
Yoo, NJ ;
Lee, JY ;
Nam, SW .
APMIS, 2005, 113 (04) :264-268
[103]   Tip60 in DNA damage response and growth control: many tricks in one HAT [J].
Squatrito, Massimo ;
Gorrini, Chiara ;
Amati, Bruno .
TRENDS IN CELL BIOLOGY, 2006, 16 (09) :433-442
[104]   Acetylation of the p53 DNA-binding domain regulates apoptosis induction [J].
Sykes, Stephen M. ;
Mellert, Hestia S. ;
Holbert, Marc A. ;
Li, Keqin ;
Marmorstein, Ronen ;
Lane, William S. ;
McMahon, Steven B. .
MOLECULAR CELL, 2006, 24 (06) :841-851
[105]   Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells [J].
Tan, Jing ;
Yang, Xiaojing ;
Zhuang, Li ;
Jiang, Xia ;
Chen, Wei ;
Lee, Puay Leng ;
Karuturi, R. K. Murthy ;
Tan, Patrick Boon Ooi ;
Liu, Edison T. ;
Yu, Qiang .
GENES & DEVELOPMENT, 2007, 21 (09) :1050-1063
[106]   Histone deacetylases: Unique players in shaping the epigenetic histone code [J].
Thiagalingam, S ;
Cheng, KH ;
Lee, HJ ;
Mineva, N ;
Thiagalingam, A ;
Ponte, JF .
EPIGENETICS IN CANCER PREVENTION: EARLY DETECTION AND RISK ASSESSMENT, 2003, 983 :84-100
[107]   Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors [J].
Verheul, Henk M. W. ;
Salumbides, Brenda ;
Van Erp, Karen ;
Hammers, Hans ;
Qian, David Z. ;
Sanni, Tolib ;
Atadja, Peter ;
Pili, Roberto .
CLINICAL CANCER RESEARCH, 2008, 14 (11) :3589-3597
[108]   Chromatin remodeling and cancer, part I: covalent histone modifications [J].
Wang, Gang G. ;
Allis, C. David ;
Chi, Ping .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (09) :363-372
[109]   Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer:: Specific role of class I histone deacetylases in vitro and in vivo [J].
Weichert, Wilko ;
Roeske, Annika ;
Niesporek, Silvia ;
Noske, Aurelia ;
Buckendahl, Ann-Christin ;
Dietel, Manfred ;
Gekeler, Volker ;
Boehm, Markus ;
Beckers, Thomas ;
Denkert, Carsten .
CLINICAL CANCER RESEARCH, 2008, 14 (06) :1669-1677
[110]   Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer [J].
Wilson, AJ ;
Byun, DS ;
Popova, N ;
Murray, LB ;
L'Italien, K ;
Sowa, Y ;
Arango, D ;
Velcich, A ;
Augenlicht, LH ;
Mariadason, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (19) :13548-13558